Scholars Central

Conference abstract

Development of a broad spectrum vaccine against invasive meningococcal disease

Authors: Graham Clarke

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

N eisseria meningitidis is the major causative agent of invasive meningococcal disease. With very fast progression leading to high mortality and morbidity rates, therapeutic intervention can be too slow. Consequently prevention is highly desirable, especially in the high risk infant and adolescent groups. The wide strain variation has been a major challenge for vaccine design. Current polysaccharide conjugate vaccines are serogroup specific. Within the B serogroup, there are a number of serosubtypes and the use of the pathogen?s B polysaccharide is inefficient, due to its occurrence in human brain tissue. ImmBio, a vaccine developer based in Cambridge UK, is developing a new class of vaccines. The technology, termed ImmBioVax, in essence mimics ex vivo the innate responses? impact on the target pathogen. This generates a multi-protein vaccine. It is self targeting and does not require the addition of an adjuvant, as these functions are performed by constitutive proteins. The candidate vaccine against invasive meningococcal disease, named MenBioVax, generates strong bactericidal antibody responses (SBA) across all the B serosubtypes tested, unlike other candidates, as well as across other serogroups, including A, C, W and Y. Thus it has the potential to both extend protection across B and replace other vaccines, in a single product. Given the clinical and regulatory importance of having a well controlled, consistent and scalable production process, ImmBio has developed a range of steps and assays to establish an appropriate process, ahead of initiating human clinical studies, which will be presented.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Graham Clarke”